The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Open Access
- 1 December 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 90 (2), 269-295
- https://doi.org/10.1093/toxsci/kfj062
Abstract
Peroxisome proliferator-activated receptors (PPARs) are ligand activated transcription factors that modulate target gene expression in response to endogenous and exogenous ligands. Ligands for the PPARs have been widely developed for the treatment of various diseases including dyslipidemias and diabetes. While targeting selective receptor activation is an established therapeutic approach for the treatment of various diseases, a variety of toxicities are known to occur in response to ligand administration. Whether PPAR ligands produce toxicity via a receptor-dependent and/or off-target-mediated mechanism(s) is not always known. Extrapolation of data derived from animal models and/or in vitro models, to humans, is also questionable. The different toxicities and mechanisms associated with administration of ligands for the three PPARs will be discussed, and important data gaps that could increase our current understanding of how PPAR ligands lead to toxicity will be highlighted.Keywords
This publication has 104 references indexed in Scilit:
- The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiationCellular Signalling, 2006
- Peroxisome proliferator-activated receptor-γ activated by ligands can inhibit human lung cancer cell growth through induction of apoptosisJournal of Huazhong University of Science and Technology [Medical Sciences], 2003
- Pioglitazone Prevents Early-Phase Hepatic Fibrogenesis Caused by Carbon TetrachlorideBiochemical and Biophysical Research Communications, 2002
- Expression of Peroxisome Proliferator-Activated Receptor γ in Renal Cell Carcinoma and Growth Inhibition by Its AgonistsBiochemical and Biophysical Research Communications, 2001
- Terminal Differentiation of Human Breast Cancer through PPARγMolecular Cell, 1998
- Effects of Gemfibrozil and Other Fibric Acid Derivatives on Blood Lipids and LipoproteinsThe Journal of Clinical Pharmacology, 1991
- Bezafibrat-induzierte Myolyse und Myoglobinurie bei Patienten mit eingeschränkter NierenfunktionJournal of Molecular Medicine, 1984
- Alkoholtoxische Veränderungen der HämatopoieseJournal of Molecular Medicine, 1981
- Clofibrate therapy and gallstone inductionDigestive Diseases and Sciences, 1978
- COMPLICATIONS DURING CLOFIBRATE TREATMENT OF NEPHROTIC-SYNDROME HYPERLIPOPROTEINÆMIAThe Lancet, 1972